Irritable Bowel Syndrome Characterized by Constipation
12
1
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
8.3%
1 terminated out of 12 trials
87.5%
+1.0% vs benchmark
50%
6 trials in Phase 3/4
86%
6 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
Botanical Tincture for Symptoms of Irritable Bowel Syndrome
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Reclassifying Constipation Using Imaging and Manometry
Food Supplement Physiomanna® Baby in Pediatric Patients
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Mode of Action of Moviprep
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation